{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:05:41Z","timestamp":1794557141950,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNRR\u2014National Center for Gene Therapy and Drugs based on RNA Technology No. CN00000041"],"award-info":[{"award-number":["PNRR\u2014National Center for Gene Therapy and Drugs based on RNA Technology No. CN00000041"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNRR\u2014National Center for Gene Therapy and Drugs based on RNA Technology No. CN00000041"],"award-info":[{"award-number":["PNRR\u2014National Center for Gene Therapy and Drugs based on RNA Technology No. CN00000041"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNRR\u2014National Center for Gene Therapy and Drugs based on RNA Technology No. CN00000041"],"award-info":[{"award-number":["PNRR\u2014National Center for Gene Therapy and Drugs based on RNA Technology No. CN00000041"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["POS4 \u201cCal-Hub-Ria\u201d No. T4-AN-09; PNRRMAD-2022-12376814"],"award-info":[{"award-number":["POS4 \u201cCal-Hub-Ria\u201d No. T4-AN-09; PNRRMAD-2022-12376814"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02699-4","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T18:45:06Z","timestamp":1743014706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Early hemodynamic impact of SGLT2 inhibitors in overweight cardiometabolic heart failure: beyond fluid offloading to vascular adaptation\u2013 a preliminary report"],"prefix":"10.1186","volume":"24","author":[{"given":"Nadia","family":"Salerno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ielapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Cersosimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assunta","family":"Di Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Armentaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Sciacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabato","family":"Sorrentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Torella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"issue":"17","key":"2699_CR1","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular Res. 2023;118(17):3272\u201387.","journal-title":"Cardiovascular Res"},{"key":"2699_CR2","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.15420\/cfr.2023.05","volume":"9","author":"B Shahim","year":"2023","unstructured":"Shahim B, Kapelios CJ, Savarese G, Lund LH. Global public health burden of heart failure: an updated review. Card Fail Rev. 2023;9:e11.","journal-title":"Card Fail Rev"},{"issue":"3","key":"2699_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jacc.2003.07.046","volume":"43","author":"K Hogg","year":"2004","unstructured":"Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function. J Am Coll Cardiol. 2004;43(3):317\u201327.","journal-title":"J Am Coll Cardiol"},{"key":"2699_CR4","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.15420\/cfr.2023.03","volume":"9","author":"CJ Kapelios","year":"2023","unstructured":"Kapelios CJ, Shahim B, Lund LH, Savarese G, Epidemiology. Clinical characteristics and Cause-specific outcomes in heart failure with preserved ejection fraction. Card Fail Rev. 2023;9:e14.","journal-title":"Card Fail Rev"},{"issue":"Suppl 2","key":"2699_CR5","doi-asserted-by":"publisher","first-page":"s24","DOI":"10.7861\/clinmedicine.18-2-s24","volume":"18","author":"AR Harper","year":"2018","unstructured":"Harper AR, Patel HC, Lyon AR. Heart failure with preserved ejection fraction. Clin Med (Lond). 2018;18(Suppl 2):s24\u20139.","journal-title":"Clin Med (Lond)"},{"issue":"36","key":"2699_CR6","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"37","key":"2699_CR7","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627\u201339.","journal-title":"Eur Heart J"},{"issue":"1","key":"2699_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamacardio.2022.4210","volume":"8","author":"FR Mc Causland","year":"2023","unstructured":"Mc Causland FR, Claggett BL, Vaduganathan M, Desai AS, Jhund P, De Boer RA, et al. Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the DELIVER randomized clinical trial. JAMA Cardiol. 2023;8(1):56.","journal-title":"JAMA Cardiol"},{"issue":"16","key":"2699_CR9","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"8","key":"2699_CR10","doi-asserted-by":"publisher","first-page":"e2330754","DOI":"10.1001\/jamanetworkopen.2023.30754","volume":"6","author":"K Chen","year":"2023","unstructured":"Chen K, Nie Z, Shi R, Yu D, Wang Q, Shao F, et al. Time to benefit of Sodium-Glucose Cotransporter-2 inhibitors among patients with heart failure. JAMA Netw Open. 2023;6(8):e2330754.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2699_CR11","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose Co-Transporter 2 (SGLT2) inhibitors: A State-of-the-Art review. JACC Basic Transl Sci. 2020;5(6):632\u201344.","journal-title":"JACC Basic Transl Sci"},{"issue":"12","key":"2699_CR12","first-page":"1399","volume":"17","author":"MC Pastore","year":"2024","unstructured":"Pastore MC, Stefanini A, Mandoli GE, Piu P, Diviggiano EE, Iuliano MA, et al. Dapagliflozin effects on cardiac deformation in heart failure and secondary clinical outcome. JACC: Cardiovasc Imaging. 2024;17(12):1399\u2013408.","journal-title":"JACC: Cardiovasc Imaging"},{"issue":"1","key":"2699_CR13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12933-024-02181-7","volume":"23","author":"A Cersosimo","year":"2024","unstructured":"Cersosimo A, Salerno N, Sabatino J, Scatteia A, Bisaccia G, De Rosa S, et al. Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance. Cardiovasc Diabetol. 2024;23(1):94.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"2699_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.4250\/jcvi.2021.0159","volume":"30","author":"CF Wee","year":"2022","unstructured":"Wee CF, Teo YH, Teo YN, Syn NL, See RM, Leong S, et al. Effects of sodium\/glucose cotransporter 2 (SGLT2) inhibitors on cardiac imaging parameters: A systematic review and Meta-analysis of randomized controlled trials. J Cardiovasc Imaging. 2022;30(3):153.","journal-title":"J Cardiovasc Imaging"},{"issue":"1","key":"2699_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12933-023-01970-w","volume":"22","author":"E Carluccio","year":"2023","unstructured":"Carluccio E, Biagioli P, Reboldi G, Mengoni A, Lauciello R, Zuchi C, et al. Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies. Cardiovasc Diabetol. 2023;22(1):235.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2699_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12933-024-02566-8","volume":"24","author":"A Fuerlinger","year":"2025","unstructured":"Fuerlinger A, Stockner A, Sedej S, Abdellatif M. Caloric restriction and its mimetics in heart failure with preserved ejection fraction: mechanisms and therapeutic potential. Cardiovasc Diabetol. 2025;24(1):21.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2699_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cardfail.2021.07.012","volume":"28","author":"S Hsu","year":"2022","unstructured":"Hsu S, Fang JC, Borlaug BA. Hemodynamics for the heart failure clinician: A State-of-the-Art review. J Card Fail. 2022;28(1):133\u201348.","journal-title":"J Card Fail"},{"issue":"2","key":"2699_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3390\/diagnostics14020136","volume":"14","author":"L Manzi","year":"2024","unstructured":"Manzi L, Sperandeo L, Forzano I, Castiello DS, Florimonte D, Paolillo R, et al. Contemporary evidence and practice on right heart catheterization in patients with acute or chronic heart failure. Diagnostics. 2024;14(2):136.","journal-title":"Diagnostics"},{"key":"2699_CR19","doi-asserted-by":"publisher","first-page":"1261022","DOI":"10.3389\/fbioe.2023.1261022","volume":"11","author":"SM Al Younis","year":"2023","unstructured":"Al Younis SM, Hadjileontiadis LJ, Stefanini C, Khandoker AH. Non-invasive technologies for heart failure, systolic and diastolic dysfunction modeling: a scoping review. Front Bioeng Biotechnol. 2023;11:1261022.","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"2699_CR20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.advms.2024.02.005","volume":"69","author":"M Anshory","year":"2024","unstructured":"Anshory M, Kuan WS, Rohman MS, Waranugraha Y, Kamila PA, Iskandar A, et al. Can non-invasive cardiac hemodynamics and fluid content system (NICaS) parameters predict acute heart failure outcomes in Caucasian and Asian patients in the emergency department? Adv Med Sci. 2024;69(1):81\u20139.","journal-title":"Adv Med Sci"},{"issue":"15","key":"2699_CR21","doi-asserted-by":"publisher","first-page":"8631","DOI":"10.3390\/ijms23158631","volume":"23","author":"SN Voorrips","year":"2022","unstructured":"Voorrips SN, Saucedo-Orozco H, S\u00e1nchez-Aguilera PI, De Boer RA, Van der Meer P, Westenbrink BD. Could SGLT2 inhibitors improve exercise intolerance in chronic heart failure?? Int J Mol Sci. 2022;23(15):8631.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2699_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2015;28(1):1\u2013e3914.","journal-title":"J Am Soc Echocardiogr"},{"issue":"4","key":"2699_CR23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","volume":"29","author":"SF Nagueh","year":"2016","unstructured":"Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2016;29(4):277\u2013314.","journal-title":"J Am Soc Echocardiogr"},{"issue":"7","key":"2699_CR24","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.echo.2010.05.010","volume":"23","author":"LG Rudski","year":"2010","unstructured":"Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: A report from the American society of echocardiography. J Am Soc Echocardiogr. 2010;23(7):685\u2013713.","journal-title":"J Am Soc Echocardiogr"},{"issue":"6","key":"2699_CR25","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/ehjci\/jey042","volume":"19","author":"LP Badano","year":"2018","unstructured":"Badano LP, Kolias TJ, Muraru D, Abraham TP, Aurigemma G, Edvardsen T, et al. Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: a consensus document of the EACVI\/ASE\/Industry task force to standardize deformation imaging. Eur Heart J - Cardiovasc Imaging. 2018;19(6):591\u2013600.","journal-title":"Eur Heart J - Cardiovasc Imaging"},{"issue":"1","key":"2699_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ehjci\/jeu184","volume":"16","author":"JU Voigt","year":"2015","unstructured":"Voigt JU, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI\/ASE\/Industry task force to standardize deformation imaging. Eur Heart J - Cardiovasc Imaging. 2015;16(1):1\u201311.","journal-title":"Eur Heart J - Cardiovasc Imaging"},{"issue":"4","key":"2699_CR27","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1378\/chest.125.4.1431","volume":"125","author":"G Cotter","year":"2004","unstructured":"Cotter G, Moshkovitz Y, Kaluski E, Cohen AJ, Miller H, Goor D, et al. Accurate, noninvasive continuous monitoring of cardiac output by Whole-Body electrical bioimpedance. Chest. 2004;125(4):1431\u201340.","journal-title":"Chest"},{"issue":"9","key":"2699_CR28","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1088\/0967-3334\/27\/9\/005","volume":"27","author":"G Cotter","year":"2006","unstructured":"Cotter G, Schachner A, Sasson L, Dekel H, Moshkovitz Y. Impedance cardiography revisited. Physiol Meas. 2006;27(9):817\u201327.","journal-title":"Physiol Meas"},{"issue":"5","key":"2699_CR29","first-page":"303","volume":"5","author":"D Du Bois","year":"1989","unstructured":"Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5(5):303\u201311. discussion 312\u2013313.","journal-title":"Nutrition"},{"issue":"1","key":"2699_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1010-7940(98)00135-3","volume":"14","author":"AJ Cohen","year":"1998","unstructured":"Cohen AJ, Arnaudov D, Zabeeda D, Schultheis L, Lashinger J, Schachner A. Non-invasive measurement of cardiac output during coronary artery bypass grafting. Eur J Cardiothorac Surg. 1998;14(1):64\u20139.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"4","key":"2699_CR31","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.hfc.2022.03.003","volume":"18","author":"NM Dixit","year":"2022","unstructured":"Dixit NM, Ziaeian B, Fonarow GC. SGLT2 inhibitors in heart failure. Heart Fail Clin. 2022;18(4):587\u201396.","journal-title":"Heart Fail Clin"},{"issue":"10","key":"2699_CR32","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","volume":"61","author":"MC Thomas","year":"2018","unstructured":"Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018;61(10):2098\u2013107.","journal-title":"Diabetologia"},{"issue":"11","key":"2699_CR33","first-page":"1028","volume":"142","author":"M Griffin","year":"2020","unstructured":"Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, et al. Empagliflozin Heart Failure: Diuret Cardiorenal Eff Circulation. 2020;142(11):1028\u201339.","journal-title":"Empagliflozin Heart Failure: Diuret Cardiorenal Eff Circulation"},{"issue":"11","key":"2699_CR34","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.3390\/ijms22115863","volume":"22","author":"G Palmiero","year":"2021","unstructured":"Palmiero G, Cesaro A, Vetrano E, Pafundi PC, Galiero R, Caturano A, et al. Impact of SGLT2 inhibitors on heart failure: from pathophysiology to clinical effects. Int J Mol Sci. 2021;22(11):5863.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2699_CR35","doi-asserted-by":"publisher","first-page":"440","DOI":"10.2337\/dc20-2604","volume":"44","author":"RA Scholtes","year":"2021","unstructured":"Scholtes RA, Muskiet MHA, Van Baar MJB, Hesp AC, Greasley PJ, Karlsson C, et al. Natriuretic effect of two weeks of Dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial. Diabetes Care. 2021;44(2):440\u20137.","journal-title":"Diabetes Care"},{"issue":"17","key":"2699_CR36","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","volume":"139","author":"M Sano","year":"2019","unstructured":"Sano M, Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation. 2019;139(17):1985\u20137.","journal-title":"Circulation"},{"issue":"9","key":"2699_CR37","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, De Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metabolism. 2013;15(9):853\u201362.","journal-title":"Diabetes Obes Metabolism"},{"issue":"1","key":"2699_CR38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13098-017-0255-8","volume":"9","author":"H Nomoto","year":"2017","unstructured":"Nomoto H, Miyoshi H, Sugawara H, Ono K, Yanagiya S, Oita M, et al. A randomized controlled trial comparing the effects of Dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin. Diabetol Metab Syndr. 2017;9(1):54.","journal-title":"Diabetol Metab Syndr"},{"issue":"15","key":"2699_CR39","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"key":"2699_CR40","doi-asserted-by":"publisher","first-page":"800490","DOI":"10.3389\/fphar.2022.800490","volume":"13","author":"J Tang","year":"2022","unstructured":"Tang J, Ye L, Yan Q, Zhang X, Wang L. Effects of sodium-Glucose cotransporter 2 inhibitors on water and sodium metabolism. Front Pharmacol. 2022;13:800490.","journal-title":"Front Pharmacol"},{"issue":"5","key":"2699_CR41","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","volume":"71","author":"M Sano","year":"2018","unstructured":"Sano M. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol. 2018;71(5):471\u20136.","journal-title":"J Cardiol"},{"issue":"1","key":"2699_CR42","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","volume":"16","author":"A Solini","year":"2017","unstructured":"Solini A, Giannini L, Seghieri M, Vitolo E, Taddei S, Ghiadoni L, et al. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol. 2017;16(1):138.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2699_CR43","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12933-019-0877-2","volume":"18","author":"A Sezai","year":"2019","unstructured":"Sezai A, Sekino H, Unosawa S, Taoka M, Osaka S, Tanaka M. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes. Cardiovasc Diabetol. 2019;18(1):76.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2699_CR44","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12933-017-0564-0","volume":"16","author":"F Shigiyama","year":"2017","unstructured":"Shigiyama F, Kumashiro N, Miyagi M, Ikehara K, Kanda E, Uchino H, et al. Effectiveness of Dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol. 2017;16(1):84.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2699_CR45","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12933-021-01295-6","volume":"20","author":"A Tanaka","year":"2021","unstructured":"Tanaka A, Shimabukuro M, Teragawa H, Okada Y, Takamura T, Taguchi I, Toyoda S, Tomiyama H, Ueda S, Higashi Y, Node K. EMBLEM investigators. Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial. Cardiovasc Diabetol. 2021;20(1):105.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2699_CR46","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/ehf2.13683","volume":"9","author":"M Nakashima","year":"2022","unstructured":"Nakashima M, Miyoshi T, Ejiri K, Kihara H, Hata Y, Nagano T, et al. Effects of Luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction. ESC Heart Fail. 2022;9(1):712\u201320.","journal-title":"ESC Heart Fail"},{"issue":"7","key":"2699_CR47","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1111\/dom.14387","volume":"23","author":"Y Matsubayashi","year":"2021","unstructured":"Matsubayashi Y, Yoshida A, Suganami H, Oe M, Sato T, Yaguchi Y, et al. Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor Tofogliflozin. Diabetes Obes Metab. 2021;23(7):1660\u20135.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2699_CR48","doi-asserted-by":"publisher","first-page":"e009156","DOI":"10.1161\/CIRCHEARTFAILURE.121.009156","volume":"15","author":"M Omar","year":"2022","unstructured":"Omar M, Jensen J, Burkhoff D, Frederiksen PH, Kistorp C, Videb\u00e6k L, et al. Effect of empagliflozin on blood volume redistribution in patients with chronic heart failure and reduced ejection fraction: an analysis from the empire HF randomized clinical trial. Circ Heart Fail. 2022;15(3):e009156.","journal-title":"Circ Heart Fail"},{"issue":"6","key":"2699_CR49","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.122.062874","volume":"147","author":"F Capone","year":"2023","unstructured":"Capone F, Vettor R, Schiattarella GG. Cardiometabolic HFpEF: NASH of the heart. Circulation. 2023;147(6):451\u20133.","journal-title":"Circulation"},{"issue":"18","key":"2699_CR50","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","volume":"118","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovascular Res. 2023;118(18):3434\u201350.","journal-title":"Cardiovascular Res"},{"issue":"2","key":"2699_CR51","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/ehjcvp\/pvaf003","volume":"11","author":"J Bogoviku","year":"2025","unstructured":"Bogoviku J, Nguyen TD, Westphal JG, Aftanski P, Moebius-Winkler S, Haertel F, et al. Acute effects of empagliflozin on left atrial and ventricular filling parameters using echocardiography-a subanalysis of the EMPAG-HF trial. Eur Heart J Cardiovasc Pharmacother. 2025;11(2):190\u20137.","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02699-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02699-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02699-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T09:05:35Z","timestamp":1743325535000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02699-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2699"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02699-4","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Local Ethics Committee (Protocol Register No. 170, May 30, 2024). All patients provided written informed consent before participating in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors listed above approved the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}